Nuvec delivers DNA directly into cells to encourage the production of anti-cancer antigens.
Nigel Theobald, chief executive, said: “In this period, we have confirmed that Nuvec works for both DNA and mRNA delivery, having produced an antibody response for both.
“We have also made progress in understanding how Nuvec behaves once loaded with DNA and mRNA.“
Improving the Nuvec particle when it has been loaded with DNA and mRNA is an essential step on its path towards use in clinical trials, Theobald added.
Lab work in both in vitro and in vivo studies and an oncology efficacy model will be the next steps.
N4 posted an unchanged loss of £552,000 in the half-year to June, while it had a cash balance of £1.2mln.